Optimization of virotherapy for cancer

Bulletin of Mathematical Biology

Volumn 72, Issue 2, 2010, Pages 469-489

  Biesecker, Matt ^a   Kimn, Jung Han ^a   Lu, Huitian ^a   Dingli, David ^b   Bajzer, Željko ^c  

^a South Dakota State University   (United States)

^b MAYO CLINIC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

Modeling virotherapy; Optimization methods

Indexed keywords

ALGORITHM; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CELL FUSION; COMPUTER SIMULATION; GENETICS; HUMAN; MEASLES VIRUS; METHODOLOGY; NEOPLASM; ONCOLYTIC VIROTHERAPY; PATHOLOGY; TRANSGENIC ORGANISM; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ALGORITHMS; ANIMALS; CELL FUSION; COMPUTER SIMULATION; HUMANS; MEASLES VIRUS; MODELS, BIOLOGICAL; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ORGANISMS, GENETICALLY MODIFIED; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77951239900     PISSN: 00928240     EISSN: 15229602     Source Type: Journal    
DOI: 10.1007/s11538-009-9456-0     Document Type: Article

References (44)

1. Anderson, B. D., Nakamura, T., Russel, S. J., Peng, K. W., 2004. High cd46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 64(14), 4919-4926.
2. Bajzer, Ž., Marušić, M., Vuk-Pavlović, S., 1996. Conceptual frameworks for mathematical modeling of tumor growth dynamics. Math. Comput. Model. 23, 31-46.
3. Bajzer, Ž., Vuk-Pavlović, S., Huzak, M., 1997. Mathematical modeling of tumor growth kinetics. In: Adam, J., Bellomo, N. (Eds.), A Survey of Models for Tumor-immune System Dynamics, pp. 89-133. Birkhäuser, New York. Chapter 3.
4. Bajzer, Ž., Carr, T., Josic, K., Russel, S. J., Dingli, D., 2008. Modelling of cancer virotherapy with recombinant measles virus. J. Theor. Biol. 252, 109-122.
5. Byrne, H. M., 2003. Modelling avascular tumor growth. In: Preziosi, L. (Ed.), Cancer Modelling and Simulation, pp. 75-120. CRC Press, Boca Raton. Chapter 4.
6. Cappuccio, A., Castiglione, F., Piccoli, B., 2007. Determination of the optimal therapeutic protocol in cancer immunotherapy. Math. Biosci. 209, 1-13.
7. Castiglione, F., Piccoli, B., 2007. Cancer immunotherapy, mathematical modelling, and optimal control. J. Theor. Biol. 247, 713-732.
8. de Pillis, L. G., Radunskaya, A. E., 2003. The dynamics of an optimally controlled tumor model: A case study. Math. Comput. Model. 37(11), 1221-1244.
9. Dingli, D., Peng, K. W., Harvey, M. E., Greipp, P. R., O'Connor, M. K., Cattaneo, R., Morris, J. C., Russell, S. J., 2004. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103, 1641-1646.
10. Dingli, D., Cascino, M. D., Josić, K., Russell, S. J., Bajzer, Ž., 2006. Mathematical modeling of cancer radiovirotherapy. Math. Biosci. 199(1), 55-78.
11. Dingli, D., Pacheco, J. M., Dispenzieri, A., Hayman, S. R., Kumar, S. K., Lacy, M. Q., Gastineau, D. A., Gertz, M. A., 2007. Serum m-spike and transplant outcome in patients with multiple myeloma. Cancer Sci. 98(7), 1035-1040.
12. Fister, K. R., Panetta, J. C., 2000. Optimally control applied to cell-cycle specific cancer chemotherapy. SIAM J. Appl. Math. 60, 1059-1072.
13. Friedman, A., Tian, J., Fulci, G., Chiocca, E., Wang, J., 2006. Glioma virotherapy: Effects of innate immune supression and increased viral replication capacity. Cancer Res. 66, 2314-2319.
14. Galanis, E., Carlson, S. K., Foster, N. R., Lowe, V., Quevedo, F., McWilliams, R. R., Grothey, A., Jatoi, A., Alberts, S. R., Rubin, J., 2008. Phase 1 trial of a pathotropic retroviral vector expressing a cytocidal cyclin g1 construct (rexin-g) in patients with advanced pancreatic cancer. Mol. Ther. 16(5), 979-984.
15. Grote, D., Russell, S. J., Cornu, T. I., Cattaneo, R., Vile, R., Poland, G. A., Fielding, A. K., 2001. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97(12), 3746-3754.
16. Hirasawa, K., Nishikawa, S. G., Normal, K. L., Coffey, M. C., Thompson, B. G., Yoon, C. S., Waisman, D. M., Lee, P. W., 2003. Systemic reovirus therapy of metastaic cancer in immune-competent mice. Cancer Res. 63(2), 348-353.
17. Kirn, D., Martuza, R. L., Zwiebel, J., 2001. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 7(7), 781-877.
18. Liu, Y., Teo, K. L., Jennings, L. S., Wang, S., 1998. On a class of optimal control problems with state jumps. J. Optim. Theory Appl. 98(1), 65-82.
19. Martin, R., Teo, K. L., 1994. Optimal Drug Administration in Cancer Chemotherapy. Singapore.
20. Mukhopadhyay, B., Bhattacharyya, R., 2008. Analysis of a virus-immune system model with two distinct delays. Nonlinear Stud. 15(1), 37-50.
21. Myers, R., Greiner, S., Harvey, M., Soeffker, D., Frenzke, M., Abraham, K., Shaw, A., Rozenblatt, S., Federspiel, M. J., Russell, S. J., Peng, K. W., 2005. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther. 12(7), 593-599.
22. Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., Romel, L., Randlev, B., Kaye, S., Kirn, D., 2001. Phase ii trial of intratumoral administration of onyx-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19(2), 289-298.
23. Ong, H. T., Timm, M. M., Greipp, P. R., Witzig, T. E., Dispenzieri, A., Russell, S. J., Peng, K. W., 2006. Oncolytic measles virus targets high cd46 expression on multiple myeloma cells. Exp. Hematol. 34(6), 713-720.
24. Paiva, L. T., Binny, C., Ferreira, S. C., Martins, M. L., 2009. A multiscale mathematical model for oncolytic virotherapy. Cancer Res. 69(3), 1205-1211.
25. Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O'Neil, J. D., Groene, W. S., Roberts, M. S., Rabin, H., Bamat, M. K., Lorence, R. M., 2002. Phase i trial of intravenous administration of pv701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20(9), 2251-2266.
26. Peng, K. W., Ahmann, G. J., Pham, L., Greipp, P. R., Cattaneo, R., Russell, S. J., 2001. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98(7), 2002-2007.
27. Peng, K. W., Facteau, S., Wegman, T., O'Kane, D., Russell, S. J., 2002. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med. 8(5), 527-531.
28. Peng, K. W., Hadac, E. M., Anderson, B. D., Myers, R., Harvey, M., Greiner, S. M., Soeffker, D., Federspiel, M. J., Russell, S. J., 2006. Pharmacokinetics of oncolytic measles virotherapy: Eventual equilibrium between virus and tumor in an ovarian cancer xenograft model 13(8), 732-738.
29. Peng, K. W., TenEyck, C. J., Galanis, E., Kalli, K. R., Hartmann, L. C., Russell, S. J., 2002. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62(16), 4656-4662.
30. Phuong, L. K., Allen, C., Peng, K. W., Giannini, C., Greiner, S., TenEyck, C. J., Mishra, P. K., Macura, S. I., Russell, S. J., Galanis, E. C., 2003. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 63(10), 2462-2469.
31. Pratt, G., Goodyear, O., Moss, P., 2007. Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol. 138(5), 563-579.
32. Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Andrews, J., Hatfield, M., Romel, L., Rubin, J., Kirn, D., 2001. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase i trial. Gene Ther. 8(21), 1618-1626.
33. Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Wein, L. M., Andrews, J., Randlev, B., Heise, C., Uprichard, M., Hatfield, M., Rome, L., Rubin, J., Kirn, D., 2002. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase ii viral, immunologic, and clinical endpoints. Cancer Res. 62(21), 6070-6079.
34. Russell, S. J., 2002. RNA viruses as virotherapy agents. Cancer Gene Ther. 9(12), 961-966.
35. Schneider, U., von Messling, V., Devaux, P., Cattaneo, R., 2002. Efficiency of measles virus entry and dissemination through different receptors. J. Virol. 76(15), 7460-7467.
36. Spratt, J. A., von Fournier, D., Spratt, J. S., Weber, E. E., 1993. Decelerating growth and human breast cancer. Cancer 71(6), 2013-2019.
37. Tao, Y., Guo, Q., 2005. The competitive dynamics between tumor cells, a replication-competent virus and an immune response. J. Math. Biol. 51(1), 37-74.
38. Todo, T., Rabkin, S. D., Sundaresan, P., Wu, A., Meehan, K. R., Herscowitz, H. B., Martuza, R. L., 1999. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther. 10(17), 2741-2755.
39. Venkataraman, P., 2001. Applied Optimization with Matlab Programming. Wiley Interscience, New York.
40. Walter, W., 1998. Ordinary Differential Equations. Springer, New York.
41. Wodarz, D., 2001. Viruses as antitumor weapons: Defining conditions for tumor remission. Cancer Res. 61, 3501-3507.
42. Wodarz, D., 2003. Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. Hum. Gene Ther. 14(2), 153-159.
43. Wu, J. T., Byrne, H. M., Kirn, D. H., Wein, L. M., 2001. Modeling and analysis of a virus that replicates selectively in tumor cells. Bull. Math. Biol. 63(4), 731-768.
44. Wu, J. T., Kirn, D. H., Wein, L. M., 2004. Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response. Bull. Math. Biol. 66(4), 605-625.